Leishmaniasis is caused by parasites transmitted through the bite of infected female insects. In its most common form, cutaneous, it causes ulcers or nodules on the skin.

The disease is endemic in 18 countries of the Americas, with the poorest people in remote and hard-to-reach tropical areas most at risk.

Currently in the region, most patients with cutaneous leishmaniasis receive a systemic treatment. This traditional treatment, which has been in use for more than 70 years, consists of a series of intravenous injections for 20 days.

Despite its efficacy, the treatment can have side effects, such renal and hepatic function alteration or arrhythmia.

In September 2022, PAHO updated its guidelines for the treatment of leishmaniasis, which include localized therapy to treat cutaneous cases with the drug meglumine antimoniate, as well as the use of thermotherapy.

Thermotherapy generates high-frequency waves that are applied locally over the lesion at a temperature of 50º Celsius for a period of 30 seconds.

The treatment consists of a single session and generates savings for the health system as well as for the affected persons and their families.

The earlier the care is sought, the greater the possibility for opting for this treatment alternative.

pll/npg/lpn